肠促胰岛素如抑胃多肽(GIP)和胰高血糖素样肽1(GLP1)可以调节β细胞增殖和细胞防御,在β细胞刺激的胰岛素分泌上发挥重要作用。GLP1可抑制胃排空、分泌和食物摄入,运用于2型糖尿病患者可明显降低餐后血糖,且发生低血糖风险小,尤其适用于老年糖尿病患者。天然GLP1在体内迅速被DPPIV降解,目前已有抗降解、长效的GLP1R配体用于临床研究。DPPIV抑制剂可以发挥降糖作用。 Intestinal insulin, such as gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP1), regulate beta cell proliferation and cellular defense and play an important role in beta-cell stimulated insulin secretion. GLP1 can inhibit gastric emptying, secretion and food intake, used in patients with type 2 diabetes can significantly reduce postprandial blood glucose, and the risk of hypoglycemia is small, especially for elderly patients with diabetes. Natural GLP1 is rapidly degraded by DPPIV in the body and there are currently anti-degradation, long-acting GLP1R ligands for clinical research. DPPIV inhibitors can exert hypoglycemic effects.